Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
A. Szpechcinski (Warsaw, Poland), M. Bryl (Poznan, Poland), G. Czyzewicz (Krakow, Poland), E. Wojda (Warsaw, Poland), D. Swiniuch (Poznan, Poland), M. Szwiec (Zielona Gora, Poland), R. Ramlau (Poznan, Poland), P. Sliwinski (Warsaw, Poland), A. Barinow-Wojewodzki (Poznan, Poland), J. Chorostowska-Wynimko (Warsaw, Poland). The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors. 4322

Member's Comments

No comment yet.

Related content which might interest you: EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017 The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Prognostic significance and correlation between Akt phosphorylation and loss of PTEN protein expression in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 458s Year: 2005 Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016 Year: 2017 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 366-372 Year: 2012 Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015 Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 Overexpression of inhibitor of DNA-binding proteins and angiogenic markers have higher impact on survival of non small cell lung cancer patients Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010 Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020 Clinical evaluation of the plasma levels of hTERT and EGFR expression as markers for early detection of non-small cell lung cancer Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009 Potential therapeutic significance of CIK cells in gefitinib resistant NSCLC with EGFR mutations Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011